Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 SUB-TYPE SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 MARKET END USER COVERAGE GRID
2.1 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 EPIDEMIOLOGY
4.2 PESTEL'S MODEL
4.3 PORTER'S 5 FORCES
5 PIPELINE ANALYSIS FOR CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET
6 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA, AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISE IN GERIATRIC POPULATION
7.1.2 RISING INVESTMENT IN RESEARCH AND DEVELOPMENT
7.1.3 RISING CLINICAL TRIALS AND PRODUCT APPROVAL
7.1.4 RISING INCIDENCE OF ACUTE MYELOID LEUKEMIA
7.2 RESTRAINTS
7.2.1 ADVERSE EFFECTS ASSOCIATED WITH ACUTE MYELOID LEUKEMIA DRUGS
7.2.2 HIGH COST OF CANCER MEDICINE
7.3 OPPORTUNITIES
7.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS
7.3.2 RISE IN HEALTHCARE EXPENDITURE
7.3.3 RISE OF INNOVATIVE THERAPIES
7.4 CHALLENGES
7.4.1 LACK OF SKILLED PROFESSIONALS
7.4.2 STRINGENT REGULATIONS
8 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY SUB-TYPE
8.1 OVERVIEW
8.2 M3 (ACUTE PROMYELOCYTIC LEUKEMIA (APL))
8.3 M2 (ACUTE MYELOBLASTIC LEUKEMIA WITH MATURATION)
8.4 M4 (ACUTE MYELOMONOCYTIC LEUKEMIA)
8.5 M0 (UNDIFFERENTIATED ACUTE MYELOBASTIC LEUKEMIA)
8.6 M1 (ACUTE MYELOBLASTIC LEUKEMIA WITH MINIMAL MATURATION)
8.7 M5 (ACUTE MONOCYTIC LEUKEMIA)
8.8 M7 (ACUTE MEGAKARYOBLASTIC LEUKEMIA)
8.9 M6 (ACUTE ERYTHROID LEUKEMIA)
9 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS
9.1 OVERVIEW
9.2 CHEMOTHERAPY
9.2.1 CYTARABINE (CYTOSAR)
9.2.2 DAUNORUBICIN
9.2.3 DOXORUBICIN
9.2.4 METHOTREXATE
9.2.5 DECITABINE
9.2.6 CLADRIBINE
9.2.7 OTHERS
9.3 TARGETED THERAPY
9.3.1 VENETOCLAX (VENCLEXTA)
9.3.2 MIDOSTAURIN (RYDAPT)
9.3.3 ENASIDENIB (IDHIFA)
9.3.4 OTHERS
9.4 IMMUNOTHERAPY
9.4.1 OBINUTUZUMAB (GAZYVA/GAZYVARO)
9.4.2 RITUXIMAB
9.4.3 INTERFERONS
9.4.4 ALEMTUZUMAB (CAMPATH)
9.4.5 OTHERS
10 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUG TYPE
10.1 OVERVIEW
10.2 BRANDED
10.2.1 CYTOSAR
10.2.2 VENCLEXTA
10.2.3 RYDAPT
10.2.4 IDHIFA
10.2.5 GAZYVA/GAZYVARO
10.2.6 CAMPATH
10.2.7 OTHERS
10.3 GENERICS
11 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 PARENTERAL
11.2.1 INTRAVENOUS
11.2.2 SUBCUTANEOUS
11.2.3 OTHERS
11.3 ORAL
11.3.1 TABLET
11.3.2 CAPSULE
11.3.3 OTHERS
11.4 OTHERS
11 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY POPULATION TYPE
11.3 OVERVIEW
11.4 GERIATRIC
11.5 ADULTS
11.5.1 MALE
11.5.2 FEMALE
11.6 PEDIATRIC
12 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY END USER
12.3 OVERVIEW
12.4 HOSPITALS
12.5 SPECIALTY CLINICS
12.6 AMBULATORY CENTERS
12.7 OTHERS
13 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 HOSPITAL PHARMACY
13.4 RETAIL PHARMACY
13.5 ONLINE PHARMACY
13.6 OTHERS
14 CENTRAL AMERICA AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY COUNTRY
14.1 COSTA RICA
14.2 PANAMA
14.3 DOMINICAN REPUBLIC
14.4 GUATEMALA
14.5 REST OF CENTRAL AMERICA
15 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC)
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 PFIZER INC.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 PRODUCT PORTFOLIO
17.1.4 RECENT DEVELOPMENT
17.2 ABBVIE INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 PRODUCT PORTFOLIO
17.2.4 RECENT DEVELOPMENTS
17.3 NOVARTIS AG
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 PRODUCT PORTFOLIO
17.3.4 RECENT DEVELOPMENT
17.4 BRISTOL-MYERS SQUIBB COMPANY
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 PRODUCT PORTFOLIO
17.4.4 RECENT DEVELOPMENT
17.5 F.HOFFMAN-LA ROCHE LTD
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENT
17.6 ASTRAZENECA
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 BOHRINGER INGELHEIM INTERNATIONAL GMBH
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENT
17.8 FRESENIUS KABI AG
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
17.9.1 COMPANY SNAPSHOT
17.9.2 REVENUE ANALYSIS
17.9.3 PRODUCT PORTFOLIO
17.9.4 RECENT DEVELOPMENTS
17.1 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.11 SUN PHARMACEUTICAL INDUSTRIES LTD.
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENT
17.12 TEVA PHARMACEUTICAL INDUSTRIES LTD
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENT
17.13 VIATRIS INC.
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENTS
18 QUESTINNAIRE
19 RELATED REPORTS
List of Table
TABLE 1 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY SUB-TYPE, 2020-2029 (USD THOUSAND)
TABLE 2 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 3 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 4 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) TARGETED THERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 5 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) IMMUNOTHERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 6 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 7 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) BRANDED IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 8 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 9 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) PARENTERAL IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 10 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ORAL IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 11 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD THOUSAND)
TABLE 12 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ADULTS IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD THOUSAND)
TABLE 13 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 14 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 15 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)
TABLE 16 COSTA RICA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY SUB-TYPE, 2020-2029 (USD THOUSAND)
TABLE 17 COSTA RICA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 18 COSTA RICA CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 19 COSTA RICA TARGETED THERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 20 COSTA RICA IMMUNOTHERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 21 COSTA RICA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 22 COSTA RICA BRANDED IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 23 COSTA RICA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 24 COSTA RICA PARENTERAL IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 25 COSTA RICA ORAL IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 26 COSTA RICA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD THOUSAND)
TABLE 27 COSTA RICA ADULTS IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD THOUSAND)
TABLE 28 COSTA RICA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 29 COSTA RICA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 30 PANAMA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY SUB-TYPE, 2020-2029 (USD THOUSAND)
TABLE 31 PANAMA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 32 PANAMA CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 33 PANAMA TARGETED THERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 34 PANAMA IMMUNOTHERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 35 PANAMA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 36 PANAMA BRANDED IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 37 PANAMA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 38 PANAMA PARENTERAL IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 39 PANAMA ORAL IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 40 PANAMA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD THOUSAND)
TABLE 41 PANAMA ADULTS IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD THOUSAND)
TABLE 42 PANAMA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 43 PANAMA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 44 DOMINICAN REPUBLIC ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY SUB-TYPE, 2020-2029 (USD THOUSAND)
TABLE 45 DOMINICAN REPUBLIC ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 46 DOMINICAN REPUBLIC CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 47 DOMINICAN REPUBLIC TARGETED THERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 48 DOMINICAN REPUBLIC IMMUNOTHERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 49 DOMINICAN REPUBLIC ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 50 DOMINICAN REPUBLIC BRANDED IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 51 DOMINICAN REPUBLIC ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 52 DOMINICAN REPUBLIC PARENTERAL IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 53 DOMINICAN REPUBLIC ORAL IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 54 DOMINICAN REPUBLIC ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD THOUSAND)
TABLE 55 DOMINICAN REPUBLIC ADULTS IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD THOUSAND)
TABLE 56 DOMINICAN REPUBLIC ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 57 DOMINICAN REPUBLIC ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 58 GUATEMALA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY SUB-TYPE, 2020-2029 (USD THOUSAND)
TABLE 59 GUATEMALA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 60 GUATEMALA CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 61 GUATEMALA TARGETED THERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 62 GUATEMALA IMMUNOTHERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 63 GUATEMALA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 64 GUATEMALA BRANDED IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 65 GUATEMALA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 66 GUATEMALA PARENTERAL IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 67 GUATEMALA ORAL IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 68 GUATEMALA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD THOUSAND)
TABLE 69 GUATEMALA ADULTS IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD THOUSAND)
TABLE 70 GUATEMALA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 71 GUATEMALA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 72 REST OF CENTRAL AMERICA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY SUB-TYPE, 2020-2029 (USD THOUSAND)
List of Figure
FIGURE 1 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: SEGMENTATION
FIGURE 2 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: DATA TRIANGULATION
FIGURE 3 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: DROC ANALYSIS
FIGURE 4 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: COUNTRY VS REGIONAL MARKET ANALYSIS
FIGURE 5 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: DBMR POSITION GRID
FIGURE 8 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: END USER COVERAGE GRID
FIGURE 9 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: SEGMENTATION
FIGURE 10 INCREASED PREVALENCE OF CANCER AND RISE IN ONGOING CLINICAL TRIALS ARE EXPECTED TO DRIVE CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET FROM 2022 TO 2029
FIGURE 11 M3 (ACUTE PROMYELOCYTIC (APL)) SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET FROM 2022 & 2029
FIGURE 12 NUMBER OF NEW CANCER CASES (ACUTE MYELOID LEUKEMIA), 2020
FIGURE 13 DRIVERS, RESTRAINS, OPPORTUNITIES AND CHALLENGES OF CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET
FIGURE 14 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY SUB-TYPE, 2021
FIGURE 15 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY SUB-TYPE, 2022-2029 (USD THOUSAND)
FIGURE 16 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY SUB-TYPE, CAGR (2022-2029)
FIGURE 17 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY SUB-TYPE, LIFELINE CURVE
FIGURE 22 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY DRUG TYPE, 2021
FIGURE 23 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY DRUG TYPE, 2022-2029 (USD THOUSAND)
FIGURE 24 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY DRUG TYPE, CAGR (2022-2029)
FIGURE 25 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 26 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 27 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD THOUSAND)
FIGURE 28 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 29 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 30 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY POPULATION TYPE, 2021
FIGURE 31 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY POPULATION TYPE, 2022-2029 (USD THOUSAND)
FIGURE 32 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY POPULATION TYPE, CAGR (2022-2029)
FIGURE 33 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 34 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY END USER, 2021
FIGURE 35 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY END USER, 2022-2029 (USD THOUSAND)
FIGURE 36 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 37 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 39 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD THOUSAND)
FIGURE 40 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 41 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 42 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: SNAPSHOT (2021)
FIGURE 43 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY COUNTRY (2021)
FIGURE 44 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 45 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 46 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY SUB-TYPE (2022-2029)
FIGURE 47 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) MARKET: COMPANY SHARE 2021 (%)
